Medicare's requirement for research participation as a condition of coverage: Is it ethical?
Article Abstract:
A debate on ethical analysis that has identified strong reasons to reject global assertions that programs linking insurance coverage to needed evidence development are coercive or unfair is presented. It is indicated that coverage with evidence development (CED) can play an important, ethically legitimate role in balancing needs for better evidence of effectiveness with the needs and desires of patients for rapid access to new innovations.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
The patents-based pharmaceutical development process: Rationale, problems, and potential reforms
Article Abstract:
The pharmaceutical industry faces substantial criticism from many directions such as financial barriers to access to drugs in both developed and developing countries, high profits, spending on advertising and marketing, and other issues. For this purpose, four complementary reforms are introduced that would have a limited but positive impact.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The use of fetal tissue in research on Parkinson's disease. Financial conflicts of interest in biomedical research
- Abstracts: Predictors of readmission for complications of coronary artery bypass graft surgery. Long-Term outcomes of coronary-artery bypass grafting versus stent implantation
- Abstracts: What's so passive about passive smoking? Secondhand smoke as a cause of atherosclerotic disease. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence
- Abstracts: Implementation of the Ottawa ankle rules in France: a multicenter randomized controlled trial. Methodological differences in clinical trials evaluating nonpharmacological and pharmacological treatments of hip and knee osteoarthritis